Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. by Groen, H. J. et al.
British Journal of Cancer (1995) 72, 1406-1411
Wt (B) 1995 Stockton Press All rights reserved 0007-0920/95 $12.00
Carboplatin- and cisplatin-induced potentiation of moderate-dose
radiation cytotoxicity in human lung cancer cell lines
HJM Groen', S Sleijfer2, C Meijer2, HH Kampinga3, AWT Konings3, EGE De Vries2 and NH
Mulder2
Departments of'Pulmonary Diseases and 2Medical Oncology, University Hospital Groningen, The Netherlands; 3Department of
Radiobiology, University ofGroningen, The Netherlands.
Summary The interaction between moderate-dose radiation and cisplatin or carboplatin was studied in a
cisplatin-sensitive (GLC4) and -resistant (GLC4-CDDP) human small-cell lung cancer cell line. Cellular toxicity
was analysed under oxic conditions with the microculture tetrazolium assay. For the platinum and radiation
toxicity with the clinically relevant dose ranges applied, this assay was used to obtain information on cell
survival after the treatments. Apart from effects on cell survival effects on DNA were also investigated.
Configurational DNA changes could be induced by platinum drugs and thereby these drugs might change the
frequency of DNA double-strand breaks (dsbs). DNA fragmentation assayed with the clamped homogeneous
electric field (CHEF) technique was used as a measure for dsbs in DNA. The radiosensitising effect of the
platinum drugs was expressed as enhancement ratio (ER) calculated directly from survival levels of the initial
slope of the curve. The highest ER for cisplatin in GLC4 was 1.39 and in GLC4-CDDP 1.38. These were all at
75% cell survival. Carboplatin showed increased enhancement with prolonged incubation up to 1.21 in GLC4
and was equally effective as cisplatin in GLC4-CDDP. According to isobologram analysis, prolonged incuba-
tion with both platinum drugs showed at least additivity with radiation for both cell lines at clinically
achievable doses. GLC4-CDDP showed cross-resistance to radiation. The radiosensitising capacity of both
lung cancer cell lines was not dependent on their platinum sensitivity. The formation of dsbs in DNA directly
after radiation was not influenced by pretreatment of either drug in the sensitive or in the resistant cell line.
Drug treatment resulted in decreased DNA extractability in control as well as in irradiated cells. Modest
enhancement ratio for radiosensitisation by platinum drugs cannot be explained on the level of dsb formation
in DNA in both cell lines. Interaction of radiation with the clinically less toxic carboplatin can be improved by
prolonged low-dose carboplatin exposure before irradiation and is as potent as cisplatin in the resistant lung
cancer cell line. This suggests an advantage in combining radiation and carboplatin in lung cancer patients.
Keywords: radiosensitisation; platinum; lung cancer; DNA double-strand breaks
Radiotherapy in locally advanced lung cancer has hardly any
impact on patient survival. In patients who are not harbour-
ing subclinical metastatic disease local failure is a major
problem (Dosoretz et al., 1992). Addition of cisplatin seems
to enhance the effect of radiation on local tumour control in
lung cancer patients (Schaake-Koning et al., 1992). Also
different tumour and mammalian cell lines under hypoxic,
and to a lesser extent under oxic conditions, show this poten-
tiation (Douple and Richmond, 1979; Carde and Laval, 1981;
Begg et al., 1987; Korbelik et al., 1989; Skov and MacPhail,
1991). Substantial toxicity, especially nephro- and gastro-
intestinal toxicity, is associated with cisplatin. Carboplatin
lacks most of the toxicities of cisplatin, especially when given
as a prolonged infusion (Smit et al., 1991), while it also
shows radiosensitising effects in tumour cell lines (Douple et
al., 1985).
Preinduction of tolerance mechanisms by radiation have
been associated with cisplatin cross-resistance (Hill et al.,
1990). Tolerance towards cisplatin can be induced, by
exposure to a low dose of this drug, leading to a platinum-
resistant human small-cell cancer cell line, GLC4-CDDP
(Hospers et al., 1988). It is not clear at the moment whether
the radiosensitising effect of cisplatin and carboplatin is
dependent on the inherent cellular sensitivity for these drugs.
We studied in GLC4-CDDP cross-resistance to radiation and
compared possible radiosensitising properties of a combined
treatment of platinum drugs and radiation in the resistant
cell line with the sensitive parent cell line. Special attention is
given to low- and moderate-dose radiation (0-8 Gy of X-
rays) and drug treatments at clinically achievable concentra-
tions, because treatment effects on the initial slope of the
survival curve seem to be a significant factor in the clinical
response of tumours to radiotherapy (Fertil and Malaise,
1981; Steel, 1993). The effects on cellular survival have quan-
titatively been expressed as ERs. Qualitative evaluations of
the effects have been performed with the use ofisobolograms
according to the concept of Steel and Peckham (1979).
The outcome of the treatment was not only assayed in
terms of cellular survival, but also as initial damage to DNA.
Cisplatin does not itselfproduce double-strand breaks (dsbs),
but it changes DNA conformationally (Chow et al., 1994;
Malinge et al., 1994). Changes in DNA tertiary structure are
linked to increased radiation sensitivity (Vaughan et al.,
1991), which has been associated with increased dsb frequen-
cies, as measured with neutral filter elution analysis
(Schwartz et al., 1991). We used clamped homogeneous elect-
ric field (CHEF) gel electrophoresis, a sensitive assay for
detecting dsbs in the low- and moderate-radiation dose
range, to study the contribution of initial DNA damage to
radiosensitisation.
Materials and methods
Chemicals
Cisplatin and carboplatin were obtained from Bristol-Myers
Squibb, Weesp, The Netherlands. Roswell Park Memorial
Institute (RPMI)-1640 medium was purchased from Gibco,
Paisley, UK, and fetal calf serum (FCS) from Sanbio, Uden,
The Netherlands. Dulbecco's modified Eagle (DME) and
Ham's F12 media were obtained from Flow Laboratories,
Irvine, UK, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazol-
ium bromide (MTT) and RNAse from Sigma, St Louis, MO,
USA. Dimethyl sulphoxide was purchased from Merck,
Darmstadt, Germany, and ethidium bromide from Serva,
Heidelberg, Germany. Low-melt agarose MP was obtained
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1995from Boehringer Mannheim, Germany. Phosphate-buffered
saline (PBS) consisted of 0.14M sodium chloride, 2.7mM
potassium chloride, 6.4 mM disodium hydrogen phosphate
dihydrate and 1.5 mM potassium hydrogen phosphate at
pH 7.4.
Cell lines
GLC4, a human small-cell lung carcinoma cell line, and its
8.6-fold cisplatin-resistant subline GLC4-CDDP were cul-
tured in RPMI-1640 medium with 10% heat-inactivated FCS
in a humidified atmosphere with 5% carbon dioxide at 37°C.
To maintain a stable resistance level GLC4-CDDP was cul-
tured under constant challenge of a monthly dose of
75 gAg ml-' cisplatin. The doubling times (mean ± s.e.) for
GLC4 and GLC4-CDDP were 24 ± 1.4 and 25 ± 2.1 h respec-
tively (Hospers et al., 1988). Before starting experiments cells
were cultured 3-6 weeks in a drug-free medium.
Drug andradiation exposure
Cells in the exponential phase of growth were plated in
25 cm2 flasks and incubated with cisplatin or carboplatin for
30 min, 4 or 24 h. Only cell culture with a viability of more
than 90%, assessed by trypan blue exclusion, were used in
experiments to limit apoptotic DNA fragmentation. There-
after, cells were transferred to 96-well microtitre plates
(100itl of cell suspension per well) for MTT assay. In the
combination experiments both platinum drugs were inc-
ubated for 30 min, 4 or 24 h before irradiation (0-8 Gy).
Cells were transferred to tubes in a volume of 0.5 ml and
either irradiated at room temperature before use in the MTT
assay or irradiated at 0°C before use in CHEF elect-
rophoresis. Radiation was carried out with Philips-Mueller
MG X-ray source (200 kV, 15 mA, half valve layer 1.05 mm
copper) at a dose rate of 5 Gy min '. Dosimetry was carried
out using a 1 cm3 Philips ionisation chamber (type 37489).
Microculture tetrazolium assay
The assay is dependent on the cellular reduction of MTT by
mitochondrial dehydrogenases of viable cells to a blue for-
mazan product, which can be measured spectrophotomet-
rically as described previously (Carmichael et al., 1987a; De
Vries et al., 1989). Before the assay was performed the linear
relationship of cell number to MTT formazan crystal forma-
tion was checked and cell growth studies were performed.
Cells were in the exponential phase ofgrowth at the moment
of testing and at least two or three cell divisions should have
taken place. Care was taken to select 1 day (at day 4) to test
the cell survival for both cell lines under these conditions.
Because the MTT assay is critically dependent on the number
ofcells plated, the amount ofkill and the time of assay, these
variables were checked at regular intervals. This was possible
when we started at 3750 cells per well for GLC4 and 15000
cells for GLC4-CDDP for 4 days in 96-well microtitre plates
(Nunc, Gibco, Paisley, UK). The differences in cell numbers
were due to the fact that the GLC4 cell line had a different
lag time after treatment with drugs or radiation and because
this cell line was metabolically more active. On the 4th day
20 ,d of MTT solution (5 mg MTT ml-' phosphate-buffered
saline; PBS) was added to each well for 3.75 h. After cent-
rifugation of the plates (30 min, 180g) supernatant was
aspirated and dimethyl sulphoxide (100%, 200ftl) was pipet-
ted to each well to dissolve crystals. The plate was
immediately read at 520 nm using a scanning microtitre well
spectrophotometer (Titertek Multiscan, Flow Laboratories).
Controls consisted of media without cells (background
extinction). At least three separate experiments were per-
formed in quadruplicate at each tested platinum concentra-
tion and/or radiation exposure. The MTT assay can be used
for measurement of survival effects after ionising radiation
under specific laboratory conditions (Carmichael et al.,
1987b; Price and McMillan, 1990). Cell survival was defined
as the growth of the treated cell populations compared with
Radiation poteniation by plaffnum in lung cancer cell lines
HJM Groen etal
1407 a
100
75
0-
> 50 .C_
cn
25
0
Carboplatin (gM)
b
L-
>3
._)
Cisplatin (gM)
C
0-
(U
C,)
Radiation (Gy)
Figure 1 Effect of carboplatin (a), cisplatin (b) and radiation (c)
on the survival (mean ± s.e.m.) of GLC4 and GLC4-CDDP cell
lines from all control experiments as measured by MTA. The
75% survival fraction is significantly different for both cell lines:
(a) P<0.001; (b) P<0.001; (c) P<0.05). For each survival
point three independent experiments in quadruplicate were per-
formed. *, GLC4-CDDP; A, GLC4.
untreated control populations. Treatment consisted of radia-
tion, platinum drugs or preincubation of either drug followed
by radiation.
CHEFelectrophoresis
A modified CHEF electrophoresis method as described ear-
lier by Blocher et al. (1989) was used. The percentage of
electrophoretically extracted DNA was quantified by
fluorescence-based image analysis of ethidium bromide-
stained gels. Cells in exponential growth were concentrated
to 2 x 107 ml-' medium (DME/Ham's F12/FCS in 2:1:1) at
37°C and added to 1% low-melt agarose in PBS at 37°C (1:1)
to form plugs. These plugs, containing 4.105 cells, were
irradiated in 200 yl of the same medium in Eppendorf vials
at 0°C. Thereafter, the plugs were transferred to 96-well
microtitre plates containing lysis buffer (proteinase KRadiation potentation by platinum in lung cancer cell lines
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0.5 mg ml' in 0.5M EDTA and 2% N-lauroylsarcosine at
pH 7.6) initially for 2 h at 4°C and subsequently for 18 h at
37C. After the plugs were rinsed with PBS, treatment with
0.2 mg ml-' RNAse in PBS followed for 50 min at 37°C. The
plugs were washed twice with TBE buffer (45 mM Tris base,
45 mM boric acid and 2 mM EDTA at pH 8.3), loaded into
the 0.5% agarose gel and sealed with low-melt agarose.
CHEF gel electrophoresis (CHEF-DR II, Bio-Rad
Laboratories, Richmond, USA) was carried out for 25 h at
14°C with a pulse time of 75 min at 40 V. The gel was stained
with ethidium bromide (0.6,tg ml- in TBE) for 12 h at 4°C
and destained with TBE at least 2 h before analysing the gel.
The plugs were removed carefully from the well and placed
horizontally on top of the gel to avoid scattering of the
bright fluorescence signal from the plug over the fragmented
DNA. The reduced fluorescence signal from the plug was
corrected for in each separate experiment by dividing the
fluorescence signal from the plug in the well by the
fluorescence signal of the plug lying horizontally on the gel.
This correction factor was calculated from at least five extra
plugs in the same gel as the original experiment was per-
formed. Thereafter, this factor was used to correct all den-
sitometric measurements coming from that gel. A linear rela-
tionship between the induction of dsb and DNA fragmenta-
tion has been observed before (Bl6cher, 1990). The percen-
tage of fragmented DNA expressed as DNA migrated out of
the plug into the gel relative to the amount which remained
into the plug was quantified using a densitometric analysis
software package (Galai, Israel) on a CUE II image analysis
system (Olympus) attached to a SIT camera. Details of this
detection method were described previously (Rosemann et
al., 1993).
Data analysis
Survival curves were established as base lines for both cell
lines treated with cisplatin and carboplatin as well as after
radiation exposure. Then survival curves for combination
treatment were performed and adjusted for drug toxicity by
starting each curve at a surviving fraction of 100%. From
these curves enhancement ratios (ERs) were obtained by
dividing the radiation dose without drug by the radiation
dose in the presence of the drug, after correction for the
drug-induced cytotoxicity, leading to a survival of 75%. This
survival level has been arbitrarily selected to be within the
initial slope of the survival curve and has been found to
correlate with clinical outcome (Fertil and Malaise, 1981;
Steel, 1993). All radiation and drug combinations were
analysed with isobologram analysis. Additivity envelopes
were calculated from the separate survival curves for radia-
tion by X-rays and cisplatin or carboplatin. First, we con-
sidered a given amount of cell kill by cisplatin or carboplatin
and then we measured the additional radiation dose needed
to reach a survival level of 75%. This was performed by
reading it off the radiation survival curve starting either from
75% survival (independent killing) or from the survival level
already reached after cisplatin or carboplatin treatment
(assuming dependent killing). Both describe an additivity
envelope in relation to which the actual combined treatment
data are compared (Steel and Peckham, 1979; Berenbaum,
1981).
Differences in cell survival and DNA fragmentation at
different drug concentrations and irradiations were compared
with Student's t-test for unpaired observations. Pearson's
correlation was performed between ER and DNA dsbs
occurring at the same drug inhibiting concentration and for
the same incubation time. Only P-values <0.05 were con-
sidered significant.
Results
Survival curves after drug or radiation treatment
Survival curves for GLC4 and GLC4-CDDP cell lines were
made for both cisplatin and carboplatin as well as for radia-
tion in clincally relevant dose ranges (Figure la, b and c). In
the GLC4 and GLC4-CDDP cell lines incubated with carbop-
latin the drug concentrations resulting in 25% growth inhibi-
tion (IC25) were respectively 12.9 and 38.8 gLM; the IC50 values
were 22.7 and 189 LM respectively (Figure la). The IC25
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Figure 2 Effect of combined treatment of 24 h preincubation
with carboplatin or cisplatin (both at IC25) and radiation (IC25)
on both human lung cancer cell lines. (a) GLC4-CDDP. -,
Untreated control; A, carboplatin and radiation. (b) GLC4. *,
Untreated control; A, carboplatin and radiation. (c) GLC4-
CDDP. *, Untreated control; A, cisplatin and radiation. (d)
GLC4. *, Untreated control; A, cisplatin and radiation.
*P<0.01.
Table I Enhancement ratios for GLC4 and GLC4-CDDP lung cancer cell lines measured at IC,0,
IC25 and IC50 concentrations of cisplatin (CDDP) and carboplatin (CBDCA) with radiation
(ID25).
Platinum incubation before irradiation
IC CDDP CBDCA CDDP CBDCA CDDP CBDCA
Cell line Drug 30min 30min 4h 4h 24h 24h
GLC4 IC,o 1.16(A) 1.05(A) 1.18(A) 0.88(An) 1.36(A) 1.21(A)
GLC4 IC25 1.21(A) 1.04(A) 1.26(A) 0.93(A) 1.39(A) 1.11(A)
GLC4 ICu 1.08(A) 0.92(A) 1.07(A) 0.95(A) 1.23(A) 1.03(A)
GLC4-CDDP IC,o 1.33(A) 0.67(A) 0.99(A) 1.13(A) 1.09(A) 1.11(A)
GLC4-CDDP IC25 0.91(An) 0.79(An) 1.13(A) 0.84(An) 1.33(A) 1.38(A)
GLC4-CDDP IC5o 0.89(An) 0.70(An) 0.99(A) 0.89(An) 0.99(A) 0.96(An)
Incubation time with each platinum drug was 30 min, 4 and 24 h before irradiation. Between
brackets the isobolographic qualification of the interaction is described: A, addition; An,
antagonism.
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_values of cisplatin in GLC4 and GLC4-CDDP cell lines were
respectively 0.81 and 6.69 EM; the ICso values were 1.2 and
10.3 JLM respectively (Figure lb). With irradiation of GLC4
and GLC4-CDDP cell lines the radiation dose resulting in
25% growth inhibition and cell death (ID25) were 0.87 and
2.25 Gy respectively; the IDo values were respectively 3.61
and 5.13 Gy. GLC4-CDDP cell line showed cross-resistance
to radiation (Figure lc).
Effect ofcombined treatments
Effects ofcisplatin and carboplatin combined with irradiation
in GLC4 and GLC4-CDDP were adjusted for drug toxicity
(Figure 2a-d). Cisplatin (IC25) combined with irradiation in
the GLC4 cell line significantly enhanced the radiation
cytotoxicity (P<0.01); in GLC4-CDDP the effect was not
significant. The effect of equitoxic carboplatin (IC25) with
irradiation was also significant in GLC4. In both cell lines the
survival effect of carboplatin (30 min and 4 h preincubation)
was less pronounced than with cisplatin. Higher cisplatin or
carboplatin doses seemed to eliminate the enhanced cell tox-
icity.
Combination treatments showed a range of ERs at
different concentrations and at different incubation times for
both cisplatin and carboplatin (Table I). Cisplatin showed
higher ERs than carboplatin. However, longer incubation
with carboplatin showed an ER that approached cisplatin's
effect in GLC4-CDDP.
Whether these enhancing effects were qualitatively different
with different doses and incubation times were evaluated by
isobologram analysis. For all the combinations ofcisplatin or
carboplatin at three different incubation times we found
mainly additive effects. In GLC4 carboplatin (ICIO, prein-
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cubation 4h) showed antagonism. In both cell lines at IC50
levels of cisplatin (preincubation 24 h) antagonism was
observed (ER in GLC4 was 0.89 and in GLC4-CDDP 0.71).
No consistent synergism was observed in both cell lines,
although in the GLC4-CDDP cell line cisplatin approached
synergism and low-dose carboplatin might be synergistic
(Figure 3a and b). In particular the combination of radiation
with cisplatin in GLC4 was only additive.
Effects ofthe combined treatment on DNAfragmentation
X-irradiation results in a linear increase of DNA extracted
from the platinum-sensitive GLC4 (y = 2.18x + 14.32, r
= 0.99, P<0.0001) (Figure 4a). Non-irradiated cells could
be extracted up to about 14% of total DNA. When radiation
was given after a 24 h pretreatment with cisplatin (IC50) or
equitoxic dose of carboplatin, the linear regression lines
representing extracted DNA in the dose range from 0-8 Gy
were parallel to the line of irradiation alone. Treatment with
cisplatin resulted in less extractable DNA at 0 Gy of X-rays.
Almost the same picture emerged from experiments with the
platinum-resistant cell line GLC4-CDDP (y = 2.83x + 10.16,
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Figure 3 Isobolograms at 75% survival level for combinations
of radiation and carboplatin (a) or cisplatin (b) both in the
GLC4-CDDP cell line. Both isobolograms show at least additive
effects of the treatment components: in the middle portion of
curve in (a) the radiation-carboplatin combination shows
synergy and for curve (b) the radiation-cisplatin combination
approaches synergy. 0, Independent cell kill; A, dependent cell
kill; A, combination of radiation and drug.
Radiation (Gy)
Figure 4 (a) Modulation of low-dose radiation-induced DNA
fragmentation (mean ± s.e.m.) by preincubating carboplatin or
cisplatin in GLC4 as measured by CHEF electrophoresis. DNA
fragmentation from base line GLC4 and GLC4-CDDP in (a) and
(b) did not differ significantly from each other (P>0.05). The
decrease in fragmentation with carboplatin was not significant
(except at 4 Gy in (a) P<0.05) and with cisplatin it was
significantly decreased at all measurement points (P<0.005, at 0
and I Gy P<0.05). *, Radiation only: A, radiation with cisp-
latin (24 h, IC5o); V, radiation with carboplatin (24 h, IC50). (b)
Modulation of low-dose radiation-induced DNA fragmentation
(mean ± s.e.m.) by preincubating carboplatin or cisplatin in
GLC4-CDDP cell line as measured by CHEF electrophoresis.
DNA fragmentation from base line GLC4-CDDP did not differ
from combined radiation with carboplatin (P> 0.05). The
decrease in fragmentation with carboplatin was not significant
and with cisplatin it was significantly decreased at all measure-
ment points (P< 0.005, at 0 and 1 Gy P<0.05). M, Radiation
only; A, radiattion with cisplatin (24 h, IC50); V, radiation with
carboplatin (24 h, IC50).
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r = 0.98, P<0.003) (Figure 4b). These cells showed less ex-
tractable DNA in the non-irradiated condition than observed
in the GLC4 cell line. The decrease in GLC4-CDDP DNA
fragmentation after preincubation with cisplatin was also
more pronounced than in the GLC4 cell line
(y = 2.30x + 10.50, r = 0.99, P<0.001 vs y = 1.95x + 13.32,
r = 0.98, P = 0.004 in GLC4), indicating that more crosslinks
of DNA occurred in GLC4-CDDP compared with the GLC4
cell line at equitoxic dose.
A correlation between ERs and DNA dsbs occurring at
the same drug dose (IC50) and the same incubation time was
not found.
Discussion
Clinical trials with cisplatin and radiation in lung cancer
showed better tumour control without enhanced normal tis-
sue toxicity (Schaake-Koning et al., 1992). Addition of cisp-
latin to radiation in late-responding tissues such as a lung,
kidney and rectum showed cytotoxic effects mainly explained
by additive mechanisms. In early-responding tissues such as
haematopoietic tissue, intestine and skin the kind of interac-
tion is uncertain (Dewit, 1987). A substantial preferential
radiosensitisation of hypoxic cells in vitro at low radiation
doses (1-4Gy) has been reported but not confirmed with
low-dose multifraction radiation in oxic and hypoxic RIF-1
tumours (Skov and MacPhail, 1991; Sun and Brown, 1993).
We studied combined treatment in human lung cancer cell
lines in regard to the therapeutic index in lung cancer.
Treatment effects on the initial slope of the survival curve
seemed to be a significant factor related to the clinical res-
ponse of tumours to radiotherapy (Fertil and Malaise, 1981;
Steel, 1993). This was the reason for selecting the arbitrary
75% survival level which was in the shoulder region of the
survival curve, where the radiosensitising effects of both
treatments were studied. We did not use survival values from
the shoulder area of the survival curve extrapolated from the
steep linear portion of the curve. The problem is the non-
linear relationship between cell survival and radiation dose
with broad limits of uncertainty in that range of the survival
curve. Therefore, apart from the enhancement ratios, the
more rigid isobolographic analysis was used to be sure to
find a relevant effect.
As can be seen in Table I the ERs with 24 h platinum
preincubation were compatible in both cell lines. The max-
imum ER approaches 1.4. This indicates that the radiosen-
sitising capacity of the tumour cells seems not to be depen-
dent on their sensitivity to platinum. Where we evaluated the
enhancing effects with isobologram analysis, it showed that
all enhancing effects are at least additive. No consistent
synergy has been noticed, although it approaches synergy
with prolonged platinum exposure. High platinum concentra-
tions in the platinum-resistant GLC4-CDDP cell line seems to
abolish radiation toxicity. The mechanism behind this
phenomenon is not yet clear. In other cell lines such as the
platinum-sensitive RIF-I and Chinese hamster cell line V79
enhanced radiation-induced cytotoxicity also suggests a role
for cisplatin as well as for prolonged carboplatin exposure in
combination with radiotherapy (Dewit, 1987; Skov and Mac-
Phail, 1991). Many animal studies, but not all, have shown
more than additive effects with high radiation doses
(Stephens et al., 1986; Coughlin and Richmond, 1989).
Cisplatin causes a range of DNA lesions of which DNA
intrastrand links are considered the most biologically relevant
for the process of cell kill. Radiation-induced cell kill is
related to DNA double-strand breaks (Frankenberg-Schw-
ager, 1990). Several ways of interaction between both
treatments may occur on the DNA level. Differences in
residual DNA breaks may be the result of inhibition DNA
repair as a result of cisplatin-induced DNA crosslinks. Alter-
natively, reduced residual double-strand breaks may be
observed owing to the priming of DNA repair processes by
platinum pretreatment, explaining differences in cell kill
between platinum-sensitive and -resistant cell lines. At the
moment research is focused on the DNA repair capacity
(rates of repair and residual damage) of tumour cells
pretreated with platinum compounds. The third possibility is
DNA or chromatin conformational changes by different
agents, associated with increased radiation sensitivity, ex-
plaining the interaction between both treatments. An in-
creased DNA accessibility for DNAase I, or an enhanced
ability to adopt positive DNA supercoiling has been
observed in a radiation-sensitive cell line as compared with a
radiation-resistant cell line (Milner et al., 1993). Also, DNA
unfolding by removal of magnesium or histon proteins
(Heussen et al., 1987), or in actively transcribed DNA sus-
tains more DNA double-strand breaks than does bulk DNA,
possibly as a result of better access to locally produced
radicals (Chiu et al., 1986). Platinum may also change DNA
conformation (Chow et al., 1994; Malinge et al., 1994) and
therefore may influence induced DNA double-strand forma-
tion, although cisplatin itself does not produce double-strand
breaks. In this study enhanced radiosensitivity by platinum
exposure was probably not caused by an enhancement of
radiation-induced dsbs in DNA.
Because longer incubations with both platinum drugs led
to ERs approaching synergism it was of interest to explore
the possibility of an enhanced formation of dsbs in DNA
directly after radiation. However, such an enhanced forma-
tion was not found. In most cases platinum pretreatment led
to a decreased DNA extractability probably caused by exten-
sive cross-linking. In this study radiation cross-resistance in
the platinum resistant cell line was observed. The ability of
this subline to form more crosslinks with platinum as com-
pared with the sensitive cell line at equitoxic dose is probably
due to the higher platinum dose used in the resistant cell line.
Whether DNA accessibility for cisplatin has changed is un-
known.
In conclusion, the platinum-resistant lung cancer cell line is
cross-resistant to radiation and shows less DNA fragmenta-
tion after cisplatin exposure than the sensitive cell line. The
radiosensitising capacity of these lung cancer cell lines is
neither dependent on their platinum sensitivity nor on initial
DNA damage by radiation. Longer platinum exposure seems
to increase ERs, but they only approach synergism. Further
exploration of prolonged exposure to carboplatin covering
the whole radiation period is warranted in lung cancer
patients.
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